Biotech | March 21, 2022
Wockhardt and Serum Life Sciences UK partner to manufacture multiple vaccines in UK
The facility will produce 150 million vaccine doses per year
The facility will produce 150 million vaccine doses per year
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Since 1993, Beghou Consulting has helped life sciences companies - especially emerging pharmaceutical companies - establish and manage commercial operations to better market and sell therapies
The investment will accelerate the overall Sarclisa development program
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Subscribe To Our Newsletter & Stay Updated
